A review of clinical aspects of breast cancer

References

• Aebi, S. (2012). Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: The CALOR trial (Chemotherapy as Adjuvant for Locally Recurrent Breast Cancer; IBCSG 27-02, NSABP B-37, BIG 1-02). Paper presented at the San Antonio Breast Cancer Symposium, 6 December 2012, Abstract S3–2.
   Google Scholar
• Anderson, G.L., Chlebowski, R.T., Aragaki, A.K., Kuller, L.H., Manson, J.E., Gass, M., … Wactawski-Wende, J. (2012). Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: Extended follow-up of the Women’s Health Initiative randomised placebo-controlled trial. Lancet Oncology, 13, 476–486.
   PubMed Web of Science ®Google Scholar
• Antoniou, A.C., Hardy, R., Walker, L., Evans, D.G., Shenton, A., Eeles, R., … Pharoah, P.D. (2008). Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. Journal of Medical Genetics, 45, 425–431.
   PubMed Web of Science ®Google Scholar
• Bachelot, T., Bourgier, C., Cropet, C., Ray-Coquard, I., Ferrero, J.M., Freyer, G., … Pujade-Lauraine, E. (2012). Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study. Journal of Clinical Oncology, 30, 2718–2724.
   PubMed Web of Science ®Google Scholar
• Baselga, J., Cortés, J., Kim, S.B., Im, S.A., Hegg, R., Im, Y.H., … CLEOPATRA Study Group. (2012a). Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. New England Journal of Medicine, 366, 109–119.
   PubMed Web of Science ®Google Scholar
• Baselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., de Azambuja, E., Aura, C., … NeoALTTO Study Team. (2012b). Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial. Lancet, 379, 633–640.
   PubMed Web of Science ®Google Scholar
• Bentzen, S.M., Agrawal, R.K., Aird, E.G., Barrett, J.M., Barrett-Lee, P.J., … Yarnold, J.R. (2008a). The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: A randomized trial. Lancet Oncology, 9, 331–341.
   PubMed Web of Science ®Google Scholar
• Bentzen, S.M., Agrawal, R.K., Aird, E.G., Barrett, J.M., Barrett-Lee, P.J., … Yarnold, J.R. (2008b). The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: A randomized trial. Lancet, 371, 1098–1107.
   PubMed Web of Science ®Google Scholar
• Beaver, J.A. & Park, B.H. (2012). The BOLERO-2 trial: The addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. Future Oncology, 8, 651–657.
   PubMed Web of Science ®Google Scholar
• Berry, D.A., Iversen, E.S. Jr, Gudbjartsson, D.F., Hiller, E.H., Garber, J.E., Peshkin, B.N., … Parmigiani, G. (2002). BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. Journal of Clinical Oncology, 20, 2701–2712.
   PubMed Web of Science ®Google Scholar
• Blackwell, K.L., Burstein, H.J., Storniolo, A.M., Rugo, H., Sledge, G., Koehler, M., … O'Shaughnessy, J. (2010). Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. Journal of Clinical Oncology, 28, 1124–1130.
   PubMed Web of Science ®Google Scholar
• Bleyer, A. & Welch, H.G. (2012). Effect of three decades of screening mammography on breast-cancer incidence. New England Journal of Medicine, 367, 1998–2005.
   PubMed Web of Science ®Google Scholar
• Chlebowski, R.T., Kuller, L.H., Prentice, R.L., Stefanick, M.L., Manson, JE., Gass, M., … Anderson, G.W. (2009). Breast cancer after use of estrogen plus progestin in postmenopausal women. New England Journal of Medicine, 360, 573–587.
   PubMed Web of Science ®Google Scholar
• Clarke, M., Collins, R., Darby, S., Davies, C., Elphinstone, P., Evans, E., … Wang, Y. (2005). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet, 366, 2087–2106.
   PubMed Web of Science ®Google Scholar
• Colditz, G.A. & Rosner, B. (2000). Cumulative risk of breast cancer to age 70 years according to risk factor status: Data from the Nurses’ Health Study. American Journal of Epidemiology, 152, 950–964.
   PubMed Web of Science ®Google Scholar
• Coombes, R.C., Kilburn, L.S., Snowdon, C.F., Paridaens, R., Coleman, R.E., Jones, S.E., … Bliss, J.M. (2007). Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): A randomized controlled trial. Lancet, 369, 559–570.
   PubMed Web of Science ®Google Scholar
• Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M. & Forbes, J.F. (2010). Effect of anastrozole and tamoxifen as adjuvant treatment for early stage breast cancer: 10 year analysis of ATAC trail. Lancet Oncology, 11, 1135–1141.
   PubMed Web of Science ®Google Scholar
• Darby, S.C., Ewertz, M., McGale, P., Bennet, AM., Blom- Goldman, U., Brønnum, D., … Hall, P. (2013). Risk of ischemic heart disease in women after radiotherapy for breast cancer. New England Journal of Medicine, 368, 987–998.
   PubMed Web of Science ®Google Scholar
• Darby, S., McGale, P., Correa, C., Taylor, C., Arriagada, R., Clarke, M., … Peto, R. (2011). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet, 378, 1707–1716.
   PubMed Web of Science ®Google Scholar
• Dawson, S.J., Rueda, O.M., Aparicio, S. & Caldas, C. (2013). A new genome-driven integrated classification of breast cancer and its implications. European Molecular Biology Organization Journal, 32, 617–628.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet, 365, 1687–1717.
   PubMed Web of Science ®Google Scholar
• Euhus, D.M. & Robinson, L. (2013). Genetic predisposition syndromes and their management. Surgical Clinics of North America, 93, 341–362.
   PubMedGoogle Scholar
• Eifel, P., Axelson, J.A., Costa, J., Crowley, J., Curran, W.J. Jr., Deshler, A., … Roter, D. (2001). National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1–3, 2000. Journal of the National Cancer Institute, 93, 979–989.
   PubMed Web of Science ®Google Scholar
• Fisher, B., Costantino, J.P., Wickerham, D.L., Redmond, C.K., Kavanah, M., Cronin, W.M., … Wolmark, N. (1998). Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute, 90, 1371–1388.
   PubMed Web of Science ®Google Scholar
• Fisher, B., Montague, E., Redmond, C., Deutsch, M., Brown, GR., Zauber, A., … Wong, A. (1980). Findings from NSABP Protocol No. B-04-comparison of radical mastectomy with alternative treatments for primary breast cancer. Cancer, 46, 1–13.
   PubMed Web of Science ®Google Scholar
• Fisher, B., Anderson, S., Bryant, J., Margolese, R.G., Deutsch, M., Fisher, E.R., … Wolmark, N. (2002). Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. New England Journal of Medicine, 347, 1233–1241.
   PubMed Web of Science ®Google Scholar
• Gail, M.H., Brinton, L.A., Byar, D.P., Corle, D.K., Green, S.B., Schairer, C. & Mulvihill, J.J. (1989). Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. Journal of the National Cancer Institute, 81, 1879–1886.
   PubMed Web of Science ®Google Scholar
• Gianni, L., Pienkowski, T., Im, Y.H., Roman, L., Tseng, L.M., Liu, M.C., … Valagussa, P. (2012). Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncololgy, 13, 25–32.
   PubMed Web of Science ®Google Scholar
• Giuliano, A.E., Kirgan, D.M., Guenther, J.M. & Morton, D.L. (1994). Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Annals of Surgery, 220, 391–398; discussion 398–401.
   PubMed Web of Science ®Google Scholar
• Giuliano, A.E., Hunt, K.K., Ballman, K.V., Beitsch, P.D., Whitworth, P.W., Blumencranz, P.W., … Morrow, M. (2011). Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial. Journal of the American Medical Association, 305, 569–575.
   PubMed Web of Science ®Google Scholar
• Goodwin, J.S., Zhang, D.D. & Ostir, G.V. (2004). Effect of depression on diagnosis, treatment, and survival of older women with breast cancer. Journal of the American Geriatrics Society, 52, 106–111.
   PubMed Web of Science ®Google Scholar
• Goss, P.E, Ingle, J.N., Pater, J.L., Martino, S., Robert, N.J., Muss, H.B. & Tu, D. (2008). Late extended adjuvant treatment with letrozole improves outcome in women with early stage breast cancer who complete 5 years of tamoxifen. Journal of Clinical Oncology, 26, 1948–1955.
   PubMed Web of Science ®Google Scholar
• Harvie, M., Hooper, L. & Howell, A.H. (2003). Central obesity and breast cancer risk: A systematic review. Obesity Review, 4, 157–173.
   PubMedGoogle Scholar
• Hancock, S.L., Tucker, M.A. & Hoppe, R.T. (1993). Breast cancer after treatment of Hodgkin's disease. Journal of the National Cancer Institute, 85, 25–31.
   PubMed Web of Science ®Google Scholar
• Halsted, W.S. (1894). The Results of Operations for the Cure of Cancer of the Breast Performed at the Johns Hopkins Hospital from June, 1889, to January, 1894. Annals of Surgery, 20, 497–555.
   PubMedGoogle Scholar
• Hendrick, R.E., Smith, R.A., Rutledge, J.H. III & Smart, C.R. (1997). Benefit of screening mammography in women aged 40–49: A new meta-analysis of randomized controlled trials. Journal of the National Cancer Institute Monographs, 22, 87–92.
   PubMedGoogle Scholar
• Kaplan, H.G., Malmgren, J.A. & Atwood, M.K. (2011). Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: A registry cohort analysis 1990–2005. BMC Cancer, 11, 260.
   PubMedGoogle Scholar
• Krag, D.N., Anderson, S.J., Julian, T.B., Brown, A.M., Harlow, S.P., Costantino, J.P., … Wolmark, N. (2010). Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: Overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncology, 11, 927–933.
   PubMed Web of Science ®Google Scholar
• Kunkler, I.H., Canney, P., van Tienhoven, G. & Russell, N.S. (2008). Elucidating the role of chest wall irradiation in ‘intermediate-risk’ breast cancer: The MRC/EORTC SUPREMO trial. Clinical Oncology, 20, 31–34.
   Web of Science ®Google Scholar
• Mamounas, E.P., Bryant, J., Lembersky, B., Fehrenbacher, L., Sedlacek, S.M., Fisher, B, … Wolmark, N. (2005). Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. Journal of Clinical Oncology, 23, 3686–3696.
   PubMed Web of Science ®Google Scholar
• Mansel, R.E., Fallowfield, L., Kissin, M., Goyal, A., Newcombe, R.G., Dixon, J.M., … Ell, P.J. (2006). Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC trial. Journal of the National Cancer Institute, 98, 599–609.
   PubMed Web of Science ®Google Scholar
• Miller, A.H., Maletic, V. & Raison, C.L. (2009). Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. Biological Psychiatry, 65, 732–741.
   PubMed Web of Science ®Google Scholar
• Perou, C.M., Sørlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, CA. & Botstein, D. (2000). Molecular portraits of human breast tumours. Nature, 406, 747–752.
   PubMed Web of Science ®Google Scholar
• Peto, R., Davies, C., Godwin, J., Gray, R., Pan, H.C., Clarke, M., … Costa, J. (2012). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet, 379, 432–444.
   PubMed Web of Science ®Google Scholar
• Qin, Y.Y., Li, H., Guo, X.J., Ye, X.F., Wei, X., Zhou, Y.H., Lu, J., … He, J. (2011). Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: A meta-analysis of 19 randomized trials with 30698 patients. Plos ONE, 6, e26946.
   PubMed Web of Science ®Google Scholar
• Richardson, H., Johnston, D. & Pater J. (2007). The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: An international breast cancer prevention trial. Current Oncology, 14, 89–96.
   PubMedGoogle Scholar
• Rimawi, M.F., Mayer, I.A., Forero, A., Nanda, R., Goetz, M.P., Rodriguez, A.A., … Chang, J.C. (2013). Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. Journal of Clinical Oncology, 31, 1726–1731.
   PubMed Web of Science ®Google Scholar
• Romond, E.H., Perez, E.A., Bryant, J., Suman, V.J., Geyer, C.E. Jr., Davidson, N.E. … Wolmark, N. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England Journal of Medicine, 353, 1673–1684.
   PubMed Web of Science ®Google Scholar
• Saslow, D., Boetes, C., Burke, W., Harms, S., Leach, M.O., Lehman, C.D. & Russell, C.A. (2007). American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA: A Cancer Journal for Clinicians, 57, 75–89.
   PubMed Web of Science ®Google Scholar
• Satin, J.R., Linden, W. & Phillips, M.J. (2009). Depression as a predictor of disease progression and mortality in cancer patients: A meta-analysis. Cancer, 115, 5349–5361.
   PubMed Web of Science ®Google Scholar
• Smith-Warner, S.A., Spiegelman, D., Yaun, S.S., van den Brandt, P.A., Folsom, A.R., Goldbohm R.A., … Hunter, D.J. (1998). Alcohol and breast cancer in women: A pooled analysis of cohort studies. Journal of the American Medical Association, 279, 535–540.
   PubMed Web of Science ®Google Scholar
• Solin, L.J., Gray, R., Baehner, F.L., Butler, S.M., Hughes, L.L., Yoshizawa, C., … Badve, S. (2013). A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. Journal of the National Cancer Institute, 5, 701–710.
   Google Scholar
• Sparano, J.A. (2006). TAILORx: Trial assigning individualized options for treatment (Rx). Clinical Breast Cancer, 7, 347–350.
   PubMed Web of Science ®Google Scholar
• Spiegel, D. & Giese-Davis, J. (2003). Depression and cancer: Mechanisms and disease progression. Biological Psychiatry, 54, 269–282.
   PubMed Web of Science ®Google Scholar
• Straver, M.E., Meijnen, P., van Tienhoven, G., van de Velde, C.J., Mansel, R.E., Bogaerts, J., … Rutgers, E.J. (2010). Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer. Journal of Clinical Oncology, 28, 731–737.
   PubMedGoogle Scholar
• Thürlimann, B., Keshaviah, A., Coates, A.S., Mouridsen, H., Mauriac, L., Forbes, J.F., … Goldhirsch, A. (2005). A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New England Journal of Medicine, 353, 2747–2757.
   PubMed Web of Science ®Google Scholar
• Urban, J.A. (1963). Extended mastectomy for breast cancer. American Journal of Surgery, 106, 399–404.
   PubMed Web of Science ®Google Scholar
• Verma, S., Miles, D., Gianni, L., Krop, I.E., Welslau, M., Baselga, J., … EMILIA Study Group. (2012). Trastuzumab emtansine for HER2-positive advanced breast cancer. New England Journal of Medicine, 367, 1783–1791.
   PubMed Web of Science ®Google Scholar
• Wellings, S.R. & Jensen, H.M. (1973). On the origin and progression of ductal carcinoma in the human breast. Journal of the National Cancer Institute, 50, 1111–1118.
   PubMed Web of Science ®Google Scholar
• Whelan, T.J., Pignol, J.P., Levine, M.N., Julian, J.A., MacKenzie, R., Parpia, S., … Shelley, W. (2010). Long-term results of hypofractionated radiation therapy for breast cancer. New England Journal of Medicine, 362, 513–520.
   PubMed Web of Science ®Google Scholar
• Wolmark, N., Wang, J., Mamounas, E., Bryant, J. & Fisher, B. (2001). Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. Journal of National Cancer Institute Monograph, 30, 96–102.
   PubMedGoogle Scholar